Cardiac Amyloidosis: Count me in before ruling me out!
This educational activity will discuss studies used in the approval of Tafamidis and other clinical trials investigating use of other drugs in the management of cardiac amyloidosis. The information provided will be educate pharmacist of the novel therapeutics use in the management of cardiac amyloidosis and pharmacists may use this information presented to advocate for formulary changes to add definitive therapy for cardiac amyloidosis to hospital formulary.
Pharmacists learning objectives
At the conclusion of this activity, pharmacists should be able to:
- Describe the different types of cardiac amyloidosis
- Recognize the clinical manifestation of cardiac amyloidosis
- Discuss diagnostic strategies for cardiac amyloidosis
- Discuss treatments, evidence to support use and emerging therapies
- Discuss symptomatic management
- Identify gaps in knowledge of cardiac amyloidosis.
|Helpful Tips for Users - Vizient CE System.pdf||134.81 KB|
|01.26.2023 - Cardiac Amyloidosis - CE Information for Credit - Live_2023.docx||127.97 KB|
Jannel Hall-Prear, PharmD, MS
Erica Dorsey, PharmD
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of Content Validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.”
Evidence-based Content: “Low/absence of evidence-based topics are mentioned within this activity”
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and ChristianaCare. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation indicating the maximum credits available. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
- 1.00 ACPE Pharmacist
- 1.00 General CE – Attendance